ERAS reduces total hospital costs and improves patient outcomes in colorectal procedures

A standardised protocol for managing patients immediately before, during and after colorectal operations not only improved clinical outcomes, it also significantly reduced overall hospital costs. One of the first studies to investigate hospital costs associated with an enhanced recovery (ERAS) pathway for colorectal patients was published in the Journal of the American College of Surgeons.

Armis granted QIDP for Ximycin for prophylaxis of surgical site infections colorectal surgery

Armis Biopharma, a late- stage clinical biopharmaceutical company with a growing pipeline of targeted anti-infective therapeutics designed to address the serious and rapidly growing phenomenon of antibiotic resistance and healthcare-associated infections, has announced that the FDA has designated the company’s lead product in development, Ximycin, as a Qualified Infectious Disease Product (QIDP) for prophylactic treatment of surgical site infections in high-risk patients undergoing non-emergent colorectal surgery.

FDA approves CleanCision wound retraction and protection system

The FDA has cleared Prescient Surgical’s CleanCision wound retraction and protection system for commercialisation in the US. Developed by surgeons and infection control experts, CleanCision is a new class of advanced technology designed to fight and defend against the most pervasive sources of surgical infection. Utilising active cleansing technology, CleanCision combines wound protection and irrigation into an intuitive and easy-to-use retraction system that actively, consistently, and continuously clears harmful bacteria that may invade the incision during surgery.